Results 131 to 140 of about 248,205 (145)

Commentary on "real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies". [PDF]

BMC Pharmacol Toxicol
Namdar AB, Keikha M.
europepmc   +1 more source

Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study. [PDF]

Blood Neoplasia
Pullarkat P, Lei M, Redd R, Rana R, Lou U, Sorial M, Rowen B, Kim EB, Medrano A, Haydu JE, Barnes J, Hochberg E, Johnson PC, Takvorian R, Lynch J, Patterson E, Thorp K, Sherburne M, McGree B, Ford J, Nemec R, Cho C, Abramson J, Soumerai JD.   +23 more
europepmc   +1 more source

The Heterogeneity of 13q Deletions in Chronic Lymphocytic Leukemia: Diagnostic Challenges and Clinical Implications. [PDF]

Genes (Basel)
Xia C, Liu G, Liu J, Ronaghy A, Tadros S, Wang W, Fang H, Zhang S, Khoury JD, Tang Z.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.

Journal of the American Medical Association (JAMA), 2023
Importance Chronic lymphocytic leukemia (CLL), defined by a minimum of 5 × 109/L monoclonal B cells in the blood, affects more than 200 000 people and is associated with approximately 4410 deaths in the US annually.
M. Shadman
semanticscholar   +1 more source

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Blood, 1999
Cellular immunophenotypic studies were performed on a cohort of randomly selected IgM(+) B-chronic lymphocytic leukemia (B-CLL) cases for which Ig V(H) and V(L) gene sequences were available. The cases were categorized based on V gene mutation status and
R. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valetto, S. L. Allen, A. Buchbinder, D. Budman, K. Dittmar, J. Kolitz, S. Lichtman, P. Schulman, V. Vinciguerra, K. Rai, M. Ferrarini, N. Chiorazzi   +15 more
semanticscholar   +1 more source